blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2752200

EP2752200 - ANTIGEN-BINDING MOLECULE INDUCING IMMUNE RESPONSE TO TARGET ANTIGEN [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  06.09.2024
Database last updated on 03.10.2024
FormerThe patent has been granted
Status updated on  29.09.2023
FormerGrant of patent is intended
Status updated on  10.04.2023
FormerExamination is in progress
Status updated on  11.11.2016
Most recent event   Tooltip06.09.2024No opposition filed within time limitpublished on 09.10.2024 [2024/41]
Applicant(s)For all designated states
Chugai Seiyaku Kabushiki Kaisha
5-1, Ukima 5-chome Kita-ku
Tokyo 115-8543 / JP
[2014/28]
Inventor(s)01 / IGAWA, Tomoyuki
c/o CHUGAI SEIYAKU KABUSHIKI KAISHA
135 Komakado 1-chome
Gotemba-shi Shizuoka 412-8513 / JP
02 / MAEDA, Atsuhiko
c/o CHUGAI SEIYAKU KABUSHIKI KAISHA
135 Komakado 1-chome
Gotemba-shi Shizuoka 412-8513 / JP
03 / HARAYA, Kenta
c/o CHUGAI SEIYAKU KABUSHIKI KAISHA
135 Komakado 1-chome
Gotemba-shi Shizuoka 412-8513 / JP
04 / TACHIBANA, Tatsuhiko
c/o CHUGAI SEIYAKU KABUSHIKI KAISHA
135 Komakado 1-chome
Gotemba-shi Shizuoka 412-8513 / JP
 [2014/28]
Representative(s)Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstrasse 3
81675 München / DE
[2023/44]
Former [2014/28]Vossius & Partner
Siebertstrasse 4
81675 München / DE
Application number, filing date12836146.628.09.2012
[2023/44]
WO2012JP75043
Priority number, dateJP2011021695830.09.2011         Original published format: JP 2011216958
[2014/28]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013047729
Date:04.04.2013
Language:JA
[2013/14]
Type: A1 Application with search report 
No.:EP2752200
Date:09.07.2014
Language:EN
[2014/28]
Type: B1 Patent specification 
No.:EP2752200
Date:01.11.2023
Language:EN
[2023/44]
Search report(s)International search report - published on:JP04.04.2013
(Supplementary) European search report - dispatched on:EP19.03.2015
ClassificationIPC:A61K39/395, A61P35/00, A61P43/00, C07K16/28, C07K16/46, C12N15/09
[2014/28]
CPC:
A61P35/00 (EP,KR); C07K16/283 (EP,KR,US); C07K16/28 (US);
A61K39/395 (RU); A61P43/00 (EP); A61K2039/505 (EP,KR,US);
C07K2317/52 (EP,KR,US); C07K2317/92 (EP,KR,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/28]  
Extension statesBANot yet paid
MENot yet paid
TitleGerman:ANTIGENBINDENDE MOLEKÜLE ZUR INDUZIERUNG EINER IMMUNANTWORT AUF EIN ZIELANTIGEN[2014/28]
English:ANTIGEN-BINDING MOLECULE INDUCING IMMUNE RESPONSE TO TARGET ANTIGEN[2014/28]
French:MOLÉCULE DE LIAISON D'UN ANTIGÈNE INDUISANT UNE RÉPONSE IMMUNITAIRE POUR CIBLER L'ANTIGÈNE[2014/28]
Entry into regional phase31.03.2014Translation filed 
31.03.2014National basic fee paid 
31.03.2014Search fee paid 
31.03.2014Designation fee(s) paid 
31.03.2014Examination fee paid 
Examination procedure31.03.2014Examination requested  [2014/28]
16.10.2015Amendment by applicant (claims and/or description)
29.06.2016Despatch of a communication from the examining division (Time limit: M06)
09.01.2017Reply to a communication from the examining division
04.08.2017Despatch of a communication from the examining division (Time limit: M06)
12.02.2018Reply to a communication from the examining division
30.07.2018Despatch of a communication from the examining division (Time limit: M06)
04.02.2019Reply to a communication from the examining division
30.08.2019Despatch of a communication from the examining division (Time limit: M06)
06.03.2020Reply to a communication from the examining division
15.06.2021Cancellation of oral proceeding that was planned for 18.06.2021
18.06.2021Date of oral proceedings (cancelled)
28.06.2021Despatch of a communication from the examining division (Time limit: M04)
05.11.2021Reply to a communication from the examining division
02.03.2022Despatch of a communication from the examining division (Time limit: M06)
12.09.2022Reply to a communication from the examining division
11.04.2023Communication of intention to grant the patent
18.08.2023Fee for grant paid
18.08.2023Fee for publishing/printing paid
18.08.2023Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  29.06.2016
Opposition(s)02.08.2024No opposition filed within time limit [2024/41]
Fees paidRenewal fee
26.09.2014Renewal fee patent year 03
25.09.2015Renewal fee patent year 04
23.09.2016Renewal fee patent year 05
22.09.2017Renewal fee patent year 06
24.09.2018Renewal fee patent year 07
24.09.2019Renewal fee patent year 08
23.09.2020Renewal fee patent year 09
23.09.2021Renewal fee patent year 10
20.09.2022Renewal fee patent year 11
21.09.2023Renewal fee patent year 12
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCZ01.11.2023
ES01.11.2023
HR01.11.2023
PL01.11.2023
RO01.11.2023
RS01.11.2023
SK01.11.2023
SM01.11.2023
NO01.02.2024
GR02.02.2024
IS01.03.2024
[2024/36]
Former [2024/35]CZ01.11.2023
ES01.11.2023
HR01.11.2023
PL01.11.2023
RO01.11.2023
RS01.11.2023
SM01.11.2023
NO01.02.2024
GR02.02.2024
IS01.03.2024
Former [2024/33]ES01.11.2023
HR01.11.2023
PL01.11.2023
RS01.11.2023
SM01.11.2023
NO01.02.2024
GR02.02.2024
IS01.03.2024
Former [2024/25]ES01.11.2023
HR01.11.2023
PL01.11.2023
RS01.11.2023
NO01.02.2024
GR02.02.2024
IS01.03.2024
Former [2024/24]ES01.11.2023
HR01.11.2023
RS01.11.2023
NO01.02.2024
GR02.02.2024
IS01.03.2024
Former [2024/20]GR02.02.2024
IS01.03.2024
Documents cited:Search[A]WO2006130834  (UNIV TEXAS [US], et al) [A] 1-26 * the whole document *;
 [A]EP2275443  (CHUGAI PHARMACEUTICAL CO LTD [JP]) [A] 1-26 * the whole document *;
 [A]  - CARLOS VACCARO ET AL, "Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels", NATURE BIOTECHNOLOGY, (20051001), vol. 23, no. 10, doi:10.1038/nbt1143, ISSN 1087-0156, pages 1283 - 1288, XP055049342 [A] 1-26 * the whole document *

DOI:   http://dx.doi.org/10.1038/nbt1143
 [A]  - RAGHAVAN M ET AL, "ANALYSIS OF THE PH DEPENDENCE OF THE NEONATAL FC RECEPTOR/IMMUNOGLOBULIN G INTERACTION USING ANTIBODY AND RECEPTOR VARIANTS", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, (19950101), vol. 34, no. 45, doi:10.1021/BI00045A005, ISSN 0006-2960, pages 14649 - 14657, XP009044243 [A] 1-26 * the whole document *

DOI:   http://dx.doi.org/10.1021/bi00045a005
 [A]  - DALL'ACQUA W F ET AL, "Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn)", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, (20060621), vol. 281, no. 33, doi:10.1074/JBC.M604292200, ISSN 0021-9258, pages 23514 - 23524, XP002404904 [A] 1-26 * the whole document *

DOI:   http://dx.doi.org/10.1074/jbc.M604292200
 [A]  - W. WANG ET AL, "Monoclonal Antibodies with Identical Fc Sequences Can Bind to FcRn Differentially with Pharmacokinetic Consequences", DRUG METABOLISM AND DISPOSITION, (20110901), vol. 39, no. 9, doi:10.1124/dmd.111.039453, ISSN 0090-9556, pages 1469 - 1477, XP055046776 [A] 1-26 * the whole document *

DOI:   http://dx.doi.org/10.1124/dmd.111.039453
 [A]  - R. J. OBER ET AL, "Exocytosis of IgG as mediated by the receptor, FcRn: An analysis at the single-molecule level", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, (20040727), vol. 101, no. 30, doi:10.1073/pnas.0402970101, ISSN 0027-8424, pages 11076 - 11081, XP055173777 [A] 1-26 * the whole document *

DOI:   http://dx.doi.org/10.1073/pnas.0402970101
 [AP]  - J. CHAPARRO-RIGGERS ET AL, "Increasing Serum Half-life and Extending Cholesterol Lowering in Vivo by Engineering Antibody with pH-sensitive Binding to PCSK9", JOURNAL OF BIOLOGICAL CHEMISTRY, (20120330), vol. 287, no. 14, doi:10.1074/jbc.M111.319764, ISSN 0021-9258, pages 11090 - 11097, XP055041205 [AP] 1-26 * the whole document *

DOI:   http://dx.doi.org/10.1074/jbc.M111.319764
 [T]  - TOMOYUKI IGAWA ET AL, "Engineered Monoclonal Antibody with Novel Antigen-Sweeping Activity In Vivo", PLOS ONE, (20130507), vol. 8, no. 5, doi:10.1371/journal.pone.0063236, page e63236, XP055172504 [T] * the whole document *

DOI:   http://dx.doi.org/10.1371/journal.pone.0063236
 [T]  - IGAWA T ET AL, "pH-dependent antigen-binding antibodies as a novel therapeutic modality", BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - PROTEINS & PROTEOMICS, (20140812), vol. 1844, no. 11, doi:10.1016/J.BBAPAP.2014.08.003, ISSN 1570-9639, pages 1943 - 1950, XP029050320 [T] * the whole document *

DOI:   http://dx.doi.org/10.1016/j.bbapap.2014.08.003
 [T]  - SIVA CHARAN DEVANABOYINA ET AL, "The effect of pH dependence of antibody-antigen interactions on subcellular trafficking dynamics", MABS, (20131101), vol. 5, no. 6, doi:10.4161/mabs.26389, ISSN 1942-0862, pages 851 - 859, XP055173157 [T] * the whole document *

DOI:   http://dx.doi.org/10.4161/mabs.26389
 [T]  - M. JACK BORROK ET AL, "pH-dependent Binding Engineering Reveals an FcRn Affinity Threshold That Governs IgG Recycling", JOURNAL OF BIOLOGICAL CHEMISTRY, (20141223), vol. 290, no. 7, doi:10.1074/jbc.M114.603712, ISSN 0021-9258, pages 4282 - 4290, XP055173622 [T] * the whole document *

DOI:   http://dx.doi.org/10.1074/jbc.M114.603712
International search[Y]WO2009125825  (CHUGAI PHARMACEUTICAL CO LTD [JP], et al);
 [Y]WO2010058860  (SHINO TEST CORP [JP], et al);
 [Y]  - IGAWA,T. ET AL., "Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization", NATURE BIOTECHNOLOGY, (2010), vol. 28, no. 11, pages 1203 - 1207, XP009153598

DOI:   http://dx.doi.org/10.1038/nbt.1691
 [Y]  - YEUNG,Y.A. ET AL., "Engineering Human IgG1 Affinity to Human Neonatal Fc Receptor: Impact of Affinity Improvement on Pharmacokinetics in Primates", JOURNAL OF IMMUNOLOGY, (2009), vol. 182, no. 12, pages 7663 - 7671, XP002566420

DOI:   http://dx.doi.org/10.4049/JIMMUNOL.0804182
 [Y]  - MI,W. ET AL., "Targeting the Neonatal Fc Receptor for Antigen Delivery Using Engineered Fc Fragments", JOURNAL OF IMMUNOLOGY, (2008), vol. 181, no. 11, pages 7550 - 7561, XP002597457
ExaminationEP2647706
    - ATHENA CHALARIS ET AL, "The soluble Interleukin 6 receptor: Generation and role in inflammation and cancer", EUROPEAN JOURNAL OF CELL BIOLOGY, WISSENSCHAFLICHE VERLAGSGESELLSCHAFT, STUTTGART, DE, vol. 90, no. 6, doi:10.1016/J.EJCB.2010.10.007, ISSN 0171-9335, (20101013), pages 484 - 494, (20101022), XP028201165

DOI:   http://dx.doi.org/10.1016/j.ejcb.2010.10.007
    - OBER RAIMUND J ET AL, "Differences in promiscuity for antibody-FcRn interactions across species: Implications for therapeutic antibodies", INTERNATIONAL IMMUNOLOGY, OXFORD UNIVERSITY PRESS, GB, (20011201), vol. 13, no. 12, doi:10.1093/INTIMM/13.12.1551, ISSN 0953-8178, pages 1551 - 1559, XP002526759

DOI:   http://dx.doi.org/10.1093/intimm/13.12.1551
    - Elvin A. Kabat ET AL, "Sequence of Proteins of Immunological Interest", Sequence of Proteins of Immunological Interest, (19910101), page FP1-2,iv,661,662,671, XP055374155
    - R. Deng ET AL, "Pharmacokinetics of Humanized Monoclonal Anti-Tumor Necrosis Factor-? Antibody and Its Neonatal Fc Receptor Variants in Mice and Cynomolgus Monkeys", Drug Metabolism and Disposition, (20100401), vol. 38, no. 4, doi:10.1124/dmd.109.031310, ISSN 0090-9556, pages 600 - 605, XP055019071

DOI:   http://dx.doi.org/10.1124/dmd.109.031310
by applicantUS3773919
 EP0058481
 EP0133988
 EP0239400
 WO9201047
 WO9203918
 WO9220791
 WO9306213
 WO9311236
 WO9312227
 WO9319172
 WO9402602
 WO9411523
 WO9425585
 WO9501438
 WO9501937
 WO9515388
 WO9602576
 WO9634096
 WO9633735
 WO9954342
 WO0042072
 WO0061739
 WO0220565
 WO0231140
 WO0232925
 WO02060919
 WO02079255
 WO03000883
 WO03029462
 WO03104453
 WO2004022754
 WO2004029207
 WO2004044011
 WO2004092219
 WO2004099249
 WO2005040229
 WO2005070963
 WO2006006693
 WO2006019447
 WO2006020114
 WO2006023403
 WO2006031370
 WO2006067913
 WO2006105338
 WO2006116260
 WO2007021841
 WO2007024249
 WO2007041635
 WO2008016854
 WO2008081008
 WO2008092117
 US2009035836
 WO2009086320
 WO2009125825
 WO2009139822
 WO2010045193
 WO2010105256
 WO2010136598
    - "The history of cancer immunotherapy.", OETTGEN, H. F.; OLD, L. J. ET AL., Biological Therapy of Cancer, (1991), pages 87 - 119
    - ZATLOUKAL K; SCHMIDT W; COTTEN M; WAGNER E; STINGL G; BIRNSTIEL ML., "Somatic gene therapy for cancer: the utility of transferrinfection in generating 'tumor vaccines'.", GENE, (1993), vol. 135, doi:doi:10.1016/0378-1119(93)90066-C, pages 199 - 207, XP024355966

DOI:   http://dx.doi.org/10.1016/0378-1119(93)90066-C
    - BRONTE V; TSUNG K; RAO JB; CHEN PW; WANG M; ROSENBERG SA; RESTIFO NP., "IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases.", J. IMMUNOL., (1995), vol. 154, pages 5282 - 5292
    - ADAMS GP; WEINER LM., "Monoclonal antibody therapy of cancer.", NAT. BIOTECHNOL., (2005), vol. 23, doi:doi:10.1038/nbt1137, pages 1147 - 1157, XP002456710

DOI:   http://dx.doi.org/10.1038/nbt1137
    - PARK S; JIANG Z; MORTENSON ED; DENG L; RADKEVICH-BROWN 0; YANG X; SATTAR H; WANG Y; BROWN NK; GREENE M, "The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity.", CANCER CELL, (2010), vol. 18, pages 160 - 170
    - TAYLOR C; HERSHMAN D; SHAH N; SUCIU-FOCA N; PETRYLAK DP; TAUB R; VAHDAT L; CHENG B; PEGRAM M; KNUTSON KL, "Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy.", CLIN. CANCER RES, (2007), vol. 13, doi:doi:10.1158/1078-0432.CCR-07-0507, pages 5133 - 43, XP002502152

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-07-0507
    - ANICE M REICHERT; CLARK J ROSENSWEIG; LAURA B FADEN; MATTHEW C DEWITZ, "Monoclonal antibody successes in the clinic.", NAT. BIOTECHNOL., (2005), vol. 23, doi:doi:10.1038/nbt0905-1073, pages 1073 - 1078, XP002555770

DOI:   http://dx.doi.org/10.1038/nbt0905-1073
    - AVLOU AK; BELSEY MJ., "The therapeutic antibodies market to 2008.", EUR. J. PHARM. BIOPHARM., (2005), vol. 59, no. 3, pages 389 - 396
    - CLARK, M., "Antibody Engineering IgG Effector Mechanisms.", CHEMICAL IMMUNOLOGY, (1997), vol. 65, pages 88 - 110
    - HORTON HM; BERNETT MJ; PONG E; PEIPP M; KARKI S; CHU SY; RICHARDS JO; VOSTIAR I; JOYCE PF; REPP R, "Potent in vitro and in vivo activity of an Fc-engineered anti-CD 19 monoclonal antibody against lymphoma and leukemia.", CANCER RES., (2008), vol. 68, pages 8049 - 8057, XP009145044
    - ZALEVSKY J; LEUNG IW; KARKI S; CHU SY; ZHUKOVSKY EA; DESJARLAIS JR; CARMICHAEL DF; LAWRENCE CE., "The impact of Fc engineering on an anti-CD19 antibody: increased Fcy receptor affinity enhances B-cell clearing in nonhuman primates.", BLOOD, (2009), vol. 113, doi:doi:10.1182/BLOOD-2008-10-182048, pages 3735 - 3743, XP002685051

DOI:   http://dx.doi.org/10.1182/BLOOD-2008-10-182048
    - JEFFERIS R; LUND J., "Interaction sites on human IgG-Fc for FcgammaR: current models.", IMMUNOL. LETT., (2002), vol. 82, doi:doi:10.1016/S0165-2478(02)00019-6, pages 57 - 65, XP002337953

DOI:   http://dx.doi.org/10.1016/S0165-2478(02)00019-6
    - CLYNES, R.; YOSHIZUMI, T.; MOROI, Y.; HOUGHTON, A.N.; RAVETCH, J.V., "Fc Receptors are required for passive and active immunity to melanoma.", PROC. NATL. ACAD. SCI. U. S. A., (1998), vol. 95, pages 652 - 656
    - CLYNES RA; TOWERS TL; PRESTA LG; RAVETCH JV., "Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets.", NAT. MED., (2000), vol. 6, doi:doi:10.1038/74704, pages 443 - 446, XP002291039

DOI:   http://dx.doi.org/10.1038/74704
    - CARTRON G; DACHEUX L; SALLES G; SOLAL-CELIGNY P; BARDOS P; COLOMBAT P; WATIER H., "Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.", BLOOD, (2002), vol. 99, doi:doi:10.1182/blood.V99.3.754, pages 754 - 758, XP002404674

DOI:   http://dx.doi.org/10.1182/blood.V99.3.754
    - NIMMERJAHN F; RAVETCH JV., "Divergent immunoglobulin g subclass activity through selective Fc receptor binding.", SCIENCE, (2005), vol. 310, doi:doi:10.1126/science.1118948, pages 1510 - 1512, XP002441364

DOI:   http://dx.doi.org/10.1126/science.1118948
    - GREENWOOD J; CLARK M; WALDMANN H., "Structural motifs involved in human IgG antibody effector functions.", EUR. J. IMMUNOL., (1993), vol. 23, doi:doi:10.1002/eji.1830230518, pages 1098 - 1104, XP009029660

DOI:   http://dx.doi.org/10.1002/eji.1830230518
    - MORGAN A; JONES ND; NESBITT AM; CHAPLIN L; BODMER MW; EMTAGE JS., "The N-terminal end of the CH2 domain of chimeric human IgG anti-HLA-DR is necessary for Clq, Fc gamma RI and Fc gamma RIII binding.", IMMUNOLOGY, (1995), vol. 86, pages 319 - 324
    - LAZAR GA; DANG W; KARKI S; VAFA 0; PENG JS; HYUN L; CHAN C; CHUNG HS; EIVAZI A; YODER SC, "Engineered antibody Fc variants with enhanced effector function.", PROC. NATL. ACAD. SCI. U. S. A., (2006), vol. 103, pages 4005 - 4010
    - SHINKAWA T; NAKAMURA K; YAMANE N; SHOJI-HOSAKA E; KANDA Y; SAKURADA M; UCHIDA K; ANAZAWA H; SATOH M; YAMASAKI M, "The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG 1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity.", J. BIOL. CHEM., (2003), vol. 278, pages 3466 - 3473
    - TSUJI T; MATSUZAKI J; KELLY MP; RAMAKRISHNA V; VITALE L; HE LZ; KELER T; ODUNSI K; OLD LJ; RITTER G, "Antibody-Targeted NY-ESO-1 to Mannose Receptor or DEC-205 In Vitro Elicits Dual Human CD8+ and CD4+ T Cell Responses with Broad Antigen Specificity.", J. IMMUNOL., (2011), vol. 186, pages 1218 - 1827
    - Epitope Mapping Protocols in Methods in Molecular Biology, (1996), vol. 66
    - Antibodies: A Laboratory Manual, COLD SPRING HARBOR LABORATORY, (1988), pages 359 - 420
    - MULLBERG ET AL., J. IMMUNOL., (1994), vol. 152, no. 10, pages 4958 - 4968
    - SAMBROOK, J ET AL., Molecular Cloning, COLD SPRING HARBOR LAB. PRESS, (1989), pages 9.47 - 9.58
    - J. IMMUNOL., (1979), vol. 123, no. 4, pages 1548 - 1550
    - CURRENT TOPICS IN MICROBIOLOGY AND IMMUNOLOGY, (1978), vol. 81, pages 1 - 7
    - C. EUR. J. IMMUNOL., (1976), vol. 6, no. 7, pages 511 - 519
    - CELL, (1976), vol. 8, no. 3, pages 405 - 415
    - NATURE, (1978), vol. 276, no. 5685, pages 269 - 270
    - J. IMMUNOL. METHODS, (1980), vol. 35, no. 1-2, pages 1 - 21
    - J. EXP. MED., (1978), vol. 148, no. 1, pages 313 - 323
    - NATURE, (1979), vol. 277, no. 5692, pages 131 - 133
    - KOHLER; MILSTEIN ET AL., METHODS ENZYMOL., (1981), vol. 73, pages 3 - 46
    - VANDAMME ET AL., EUR. J. BIOCHEM., (1990), vol. 192, no. 3, pages 767 - 775
    - BIOCHEMISTRY, (1979), vol. 18, no. 24, pages 5294 - 5299
    - ANAL. BIOCHEM., (1987), vol. 162, no. 1, pages 156 - 159
    - PROC. NATL. ACAD. SCI. USA, (1988), vol. 85, no. 23, pages 8998 - 9002
    - NUCLEIC ACIDS RES., (1989), vol. 17, no. 8, pages 2919 - 2932
    - EBERT, K. M. ET AL., BIO/TECHNOLOGY, (1994), vol. 12, no. 7, pages 699 - 702
    - CANCER RES., (1993), vol. 53, pages 851 - 856
    - BERNASCONI ET AL., SCIENCE, (2002), vol. 298, pages 2199 - 2202
    - SPRINGER ET AL., CELL, (2000), vol. 102, pages 275 - 277
    - KAWASAKI; KRETSINGER, PROTEIN PROF., (1995), vol. 2, pages 305 - 490
    - MONCRIEF ET AL., J. MOL. EVOL., (1990), vol. 30, pages 522 - 562
    - CHAUVAUX ET AL., BIOCHEM. J., (1990), vol. 265, pages 261 - 265
    - BAIROCH; COX, FEBS LETT., (1990), vol. 269, pages 454 - 456
    - DAVIS, NEW BIOL., (1990), vol. 2, pages 410 - 419
    - SCHAEFER ET AL., GENOMICS, (1995), vol. 25, pages 638 - 643
    - ECONOMOU ET AL., EMBO J., (1990), vol. 9, pages 349 - 354
    - WURZBURG ET AL., STRUCTURE, (2006), vol. 14, no. 6, pages 1049 - 1058
    - TOMLINSON ET AL., J. MOL. BIOL., (1992), vol. 227, pages 776 - 798
    - WILLIAMS; WINTER, EUR. J. IMMUNOL., (1993), vol. 23, pages 1456 - 1461
    - COX ET AL., NAT. GENETICS, (1994), vol. 7, pages 162 - 168
    - MATSUDA ET AL., J. EXP. MED., (1998), vol. 188, pages 1973 - 1975
    - KAWASAKI ET AL., EUR. J. IMMUNOL., (2001), vol. 31, pages 1017 - 1028
    - SCHABLE; ZACHAU, BIOL. CHEM. HOPPE SEYLER, (1993), vol. 374, pages 1001 - 1022
    - BRENSING-KUPPERS ET AL., GENE, (1997), vol. 191, pages 173 - 181
    - KAWASAKI ET AL., GENOME RES., (1997), vol. 7, pages 250 - 261
    - WU ET AL., J. EXP. MED., (1970), vol. 132, pages 211 - 250
    - KUNKEL ET AL., PROC. NATL. ACAD. SCI. USA, (1985), vol. 82, pages 488 - 492
    - LEE; RICHARDS, J. MOL. BIOL., (1971), vol. 55, pages 379 - 400
    - CONNOLLY, J. APPL. CRYST., (1983), vol. 16, pages 548 - 558
    - PACIOS, COMPUT. CHEM., (1994), vol. 18, no. 4, pages 377 - 386
    - J. MOL. MODEL., (1995), vol. 1, pages 46 - 53
    - GEJIMA ET AL., HUMAN ANTIBODIES, (2002), vol. 11, pages 121 - 129
    - CARDOSO ET AL., SCAND. J. IMMUNOL., (2000), vol. 51, pages 337 - 344
    - BIOORG. MED. CHEM., (2003), vol. 11, no. 17, pages 3761 - 2768
    - ANNU. REV. BIOPHYS. BIOMOL. STRUCT., (2006), vol. 35, pages 225 - 249
    - PROC. NATL. ACAD. SCI. U.S.A., (2003), vol. 100, no. 11, pages 6353 - 6357
    - GHETIE, IMMUNOL. TODAY, (1997), vol. 18, no. 12, pages 592 - 598
    - RAGHAVAN ET AL., IMMUNITY, (1994), vol. 1, pages 303 - 315
    - JOURNAL OF IMMUNOLOGY, (2009), vol. 182, pages 7663 - 7671
    - PROC. NATL. ACAD. SCI. USA, (2006), vol. 103, no. 11, pages 4005 - 4010
    - DAVIS ET AL., IMMUNOLOGICAL REVIEWS, (2002), vol. 190, pages 123 - 136
    - CURR. OPIN. BIOTECHNOL., (2009), vol. 20, no. 6, pages 685 - 91
    - CURR. OPIN. IMMUNOL., (2008), vol. 20, no. 4, pages 460 - 470
    - PROTEIN ENG. DES. SEL., (2010), vol. 23, no. 4, pages 195 - 202
    - PROTEIN ENGINEERING, (1996), vol. 9, no. 3, pages 299 - 305
    - HEINRICH ET AL., BIOCHEM. J., (1998), vol. 334, pages 297 - 314
    - ISHIKAWA ET AL., J. CLIN. EXP. HEMATOPATHOL., (2006), vol. 46, no. 2, pages 55 - 66
    - J. PHARM. BIOMED. ANAL., (20110715), vol. 55, no. 5, pages 878 - 88
    - OVERES ET AL., J. IMMUNOTHER., (2009), vol. 32, pages 539 - 551
    - J. BIOMED. MATER. RES., (1981), vol. 15, pages 267 - 277
    - CHEMTECH, (1982), vol. 12, pages 98 - 105
    - BIOPOLYMERS, (1983), vol. 22, pages 547 - 556
    - Remington's Pharmaceutical Science, MARK PUBLISHING COMPANY
    - THE JOURNAL OF IMMUNOLOGY, (2009), vol. 182, pages 7663 - 7671
    - EUR. J. IMMUNOL., (1992), vol. 22, pages 1989 - 93
    - JACKSON LABORATORIES, METHODS MOL. BIOL., (2010), vol. 602, pages 93 - 104
    - J. IMMUNOL., (2008), vol. 181, pages 7550 - 61
    - J. IMMUNOL., (2008), vol. 181, pages 7550 - 7561
    - J. IMMUNOL., (2011), vol. 186, pages 1218 - 1227
    - PROTEIN SCIENCE, (1995), vol. 4, pages 2411 - 2423
    - J. BIOL. CHEM., (2008), vol. 283, no. 37, pages 25140 - 25149
    - J. MOL. BIOL., (2000), vol. 296, pages 57 - 86
    - PROC. NATL. ACAD. SCI. USA, (2009), vol. 106, no. 48, pages 20216 - 20221
    - KABAT, E.A. ET AL., Sequences of proteins of immunological interest, NIH PUBLICATION, (1991), vol. 91
    - METHODS MOL BIOL., (2002), vol. 178, pages 87 - 100
    - J. IMMUNOL. METHODS., (2008), vol. 332, no. 1-2, pages 2 - 9
    - J. IMMUNOL. METHODS., (2001), vol. 247, no. 1-2, pages 191 - 203
    - BIOTECHNOL. PROG., (2002), vol. 18, no. 2, pages 212 - 20
    - MOL. CELL PROTEOMICS, (2003), vol. 2, no. 2, pages 61 - 9
    - METHODS MOL. BIOL., (2002), vol. 178, pages 133 - 145
    - DALL' ACQUA ET AL., J. IMMUNOL., (2002), vol. 169, no. 9, pages 5171 - 5180
    - YEUNG ET AL., J. IMMUNOL., (2009), vol. 182, no. 12, pages 7663 - 7671
    - DATTA-MANNAN ET AL., J. BIOL. CHEM., (2007), vol. 282, no. 3, pages 1709 - 1717
    - MULLBERG ET AL., J. IMMUNOL., (1994), vol. 152, pages 4958 - 4968
    - FEBS LETTER 11483, vol. 309, no. 1, pages 85 - 88
    - BLOOD, (2008), vol. 112, pages 3959 - 3969
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.